Skip to Content

Lumify Approval History

  • FDA approved: Yes (First approved December 22nd, 2017)
  • Brand name: Lumify
  • Generic name: brimonidine tartrate
  • Dosage form: Ophthalmic Solution
  • Company: Bausch & Lomb Inc.
  • Treatment for: Ocular Redness

Lumify (brimonidine tartrate) is an over-the-counter (OTC) formulation of the alpha-adrenergic agonist brimonidine indicated for use in the treatment of ocular redness.

Brimonidine was first approved by the FDA in 1996 at higher doses for the reduction of intraocular pressure in glaucoma patients. Lumify is a lower dose brimonidine formulation intended to treat ocular redness by selectively constricting veins in the eye, increasing the availability of oxygen to surrounding tissue, and thereby reducing the potential risk of these side effects.

Development History and FDA Approval Process for Lumify

Dec 22, 2017Approval Bausch + Lomb Receives FDA Approval of Lumify (brimonidine tartrate) Over-the-Counter Eye Drop for the Treatment of Eye Redness

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.